Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure
Zhongping Duan,1,* Shaojie Xin,2,* Jing Zhang,1 Shaoli You,2 Yu Chen,1 Hongling Liu,2 Sujun Zheng,1 Zheng Li,3 Robert Ashley,3 Michael Millis4 1Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China; 2Department of Infectious Disease, Division III, 3...
Guardado en:
Autores principales: | Duan Z, Xin S, Zhang J, You S, Chen Y, Liu H, Zheng S, Li Z, Ashley R, Millis M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/095eee53a72447c1b0513f0c1a3244b2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure
por: Ben F.J. Goudsmit, et al.
Publicado: (2021) -
Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience
por: Motoh Iwasa, et al.
Publicado: (2021) -
Acute Liver Failure due to Hepatitis A Virus
por: Reem Shammout, et al.
Publicado: (2021) -
Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case–Control Study
por: Azarkar G, et al.
Publicado: (2019) -
Step by Step: Managing the Complications of Cirrhosis
por: Perez IC, et al.
Publicado: (2021)